Lexicon Pharmaceuticals LXRX Proceeds from disposition of marketable securities and other investments
Proceeds from disposition of marketable securities and other investments at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's proceeds from disposition of marketable securities and other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's proceeds from disposition of marketable securities and other investments?
- Lexicon Pharmaceuticals (LXRX) reported proceeds from disposition of marketable securities and other investments of $35.7M in Q1 2026.
- How has Lexicon Pharmaceuticals's proceeds from disposition of marketable securities and other investments changed year-over-year?
- Lexicon Pharmaceuticals's proceeds from disposition of marketable securities and other investments decreased by 66.2% year-over-year, from $105.55M to $35.7M.
- What is the long-term trend for Lexicon Pharmaceuticals's proceeds from disposition of marketable securities and other investments?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's proceeds from disposition of marketable securities and other investments has grown at a 61.0% compound annual growth rate (CAGR), from $37.59M to $252.86M.
- What does proceeds from disposition of marketable securities and other investments mean?
- This represents the cash inflows generated from the sale, maturity, or redemption of investment securities. It serves as a source of liquidity, often used to fund ongoing operations or reinvest in the business. Monitoring these proceeds helps investors understand the company's ability to convert its investment portfolio back into cash.